Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update
07 mai 2020 16h05 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva
22 avr. 2020 16h05 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development...
Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update
11 mars 2020 16h05 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
14 nov. 2019 07h30 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer
30 oct. 2019 16h05 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference
29 oct. 2019 08h30 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
03 oct. 2019 16h01 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
30 sept. 2019 01h00 HE
|
Entasis Therapeutics Holdings Inc.
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...
Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
03 sept. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
12 août 2019 07h30 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...